Agreements reached under this partnership
Capital and Business Alliance- 1
We will work to build the technological foundation supporting a new dementia care model through a multimodal assessment method combining digital and blood biomarkers.
- 2
Basic attributes, including age and sex
- 3
Cognitive function assessment
- 4
MRI image analysis AI
- 5
Blood biomarkers
- 6
The parties will support the establishment of a referral pathway under which risk assessments using digital and blood biomarkers are conducted at local clinics, health screening facilities and brain checkup centers, with people assessed as high risk referred to memory clinics and advanced medical institutions.
- 7
Establishment of a system for the early detection of dementia in local communities
- 8
Medical cooperation to appropriately connect people requiring specialized diagnosis and treatment with specialized medical services
- 9
Effective use of limited specialized medical resources
- 10
Narrowing regional disparities in dementia care and standardizing the quality of care
- 11
Extending Healthy Life Expectancy
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
At this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社 Splink |
| Alliance partner's business activities | Brain healthcare business; medical data platform business |
| Alliance partner's location | Minato-ku, Tokyo |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | We will work to build the technological foundation supporting a new dementia care model through a multimodal assessment method combining digital and blood biomarkers., Basic attributes, including age and sex, Cognitive function assessment, MRI image analysis AI, Blood biomarkers, The parties will support the establishment of a referral pathway under which risk assessments using digital and blood biomarkers are conducted at local clinics, health screening facilities and brain checkup centers, with people assessed as high risk referred to memory clinics and advanced medical institutions., Establishment of a system for the early detection of dementia in local communities, Medical cooperation to appropriately connect people requiring specialized diagnosis and treatment with specialized medical services, Effective use of limited specialized medical resources, Narrowing regional disparities in dementia care and standardizing the quality of care, Extending Healthy Life Expectancy |
| Impact on Business Performance | At this time, we expect this basic agreement to have a limited impact on the company's near-term results. If it becomes clear that the agreement will have a material impact, we will disclose the information promptly. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To support タウンズ's expansion into the chronic disease field and address the social issue of early dementia detection and intervention. The rationale cited is the combination of Splink's cognitive function assessment and medical AI technologies with タウンズ's expertise in biomarkers and in vitro diagnostic products.